	US 12,403,120 B2
	Pharmaceutical compositions of furosemide and uses thereof
Pieter Muntendam, Boxford, MA (US)
Assigned to SQ Innovation AG, Zug (CH)
Appl. No. 17/311,634
Filed by SQ Innovation AG, Zug (CH)
PCT Filed Dec. 10, 2019, PCT No. PCT/EP2019/084446 § 371(c)(1), (2) Date Jun. 7, 2021, PCT Pub. No. WO2020/120482, PCT Pub. Date Jun. 18, 2020.
Claims priority of provisional application 62/777,384, filed on Dec. 10, 2018.
Prior Publication US 2022/0008374 A1, Jan. 13, 2022
Int. Cl. A61K 31/341 (2006.01); A61K 9/00 (2006.01); A61K 9/08 (2006.01); A61K 31/635 (2006.01); A61K 47/18 (2017.01)

CPC A61K 31/341 (2013.01) [A61K 9/08 (2013.01); A61K 47/18 (2013.01)]

26 Claims

1. A pharmaceutical composition, comprising:

furosemide, or a pharmaceutically acceptable salt, hydrate or ester thereof; and

tris(hydroxymethyl)aminomethane; wherein

the furosemide is present in the pharmaceutical composition at a concentration from about 10 mg/mL to about 30 mg/mL;

the tris(hydroxymethyl)aminomethane is present in the pharmaceutical composition at a concentration of less than or equal to 40 mM; and

the pharmaceutical composition has a pH value from about 8.0 to about 8.5;

wherein the pharmaceutical composition has a molar ratio of the tris(hydroxymethyl)aminomethane to the furosemide of less than or equal to 0.8.